Illumina: Navigating Headwinds As China Bans Instruments And Roche Enters The NGS Race
Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...
Investing1d
Illumina’s SWOT analysis: next-gen sequencing leader faces headwinds
Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a ...
GEN15d
The State of Multiomics & NGS
In GEN‘s The State of Multiomics & NGS virtual summit ... sessions hosted and organized by the summit sponsors – Illumina, Sampled, Scale Biosciences, and Standard BioTools.
pharmaphorum14d
DNA sequencer Element Bio raises $277m to take on Illumina
Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...
Yahoo Finance6d
Illumina, Inc. (ILMN)
The new omics solutions surpass industry standards for scale, accuracy, and reliability because t Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based ...
Citi cuts Illumina target, places on ‘negative catalyst watch’
Citi lowered the firm’s price target on Illumina (ILMN) to $90 from $130 and keeps a Neutral rating on the shares. The firm also placed the ...